Coherus Oncology (CHRS) Insider Trading & Ownership $0.87 -0.01 (-1.12%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Coherus Oncology (NASDAQ:CHRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.08%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$73.99K Get CHRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Coherus Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CHRS Insider Buying and Selling by Quarter Coherus Oncology Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/23/2025Mats WahlstromDirectorSell99,988$0.74$73,991.12 (Data available from 1/1/2013 forward) CHRS Insider Trading Activity - Frequently Asked Questions Who is on Coherus Oncology's Insider Roster? The list of insiders at Coherus Oncology includes Dennis M Lanfear, and Mats Wahlstrom. Learn more on insiders at CHRS. What percentage of Coherus Oncology stock is owned by insiders? 8.08% of Coherus Oncology stock is owned by insiders. Learn more on CHRS's insider holdings. Which Coherus Oncology insiders have been selling company stock? The following insiders have sold CHRS shares in the last 24 months: Dennis M Lanfear ($450,662.00), and Mats Wahlstrom ($73,991.12). How much insider selling is happening at Coherus Oncology? Insiders have sold a total of 323,088 Coherus Oncology shares in the last 24 months for a total of $524,653.12 sold. Coherus Oncology Key ExecutivesMr. Dennis M. Lanfear (Age 69)Chairman, President & CEO Compensation: $1.82MMr. Bryan J. McMichael (Age 45)Former Interim CFO, Principal Financial and Acc. Off., SVP-Acc. & Corporate Controller Compensation: $615.07kMr. Paul Reider (Age 54)Chief Commercial Officer Compensation: $854.06kMr. Richard L. HameisterChief Technical OfficerMs. Jami TaylorVice President of Investor RelationsMr. Andy RittenbergExecutive Vice President of General CounselCheston TurbyfillVice President of CommunicationsMr. Scott SaywellExecutive Vice President of Corporate DevelopmentMs. Rebecca Sunshine (Age 61)Chief Human Resources Officer Mr. Michael ChenSenior Vice President of Commercial Analytics & Trade More Insider Trading Tools from MarketBeat Related Companies PVLA Insider Transactions ERAS Insider Transactions TECX Insider Transactions ITOS Insider Transactions VIGL Insider Transactions AQST Insider Transactions ETON Insider Transactions ATXS Insider Transactions FULC Insider Transactions PRTA Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CHRS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts